New immunotherapy combo shows promise for young cancer patients
NCT ID NCT06521567
First seen Nov 12, 2025 · Last updated May 21, 2026 · Updated 22 times
Summary
This study tests two immunotherapy drugs, cobolimab and dostarlimab, together in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study involves about 83 participants and is currently active but not recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Los Angeles, California, 90048, United States
-
GSK Investigational Site
Iowa City, Iowa, 52242, United States
-
GSK Investigational Site
Hackensack, New Jersey, 07601, United States
-
GSK Investigational Site
Cincinnati, Ohio, 45229, United States
-
GSK Investigational Site
Providence, Rhode Island, 02903, United States
-
GSK Investigational Site
Madison, Wisconsin, 53792, United States
-
GSK Investigational Site
Brno, 61300, Czechia
-
GSK Investigational Site
Phaha 5, 15006, Czechia
-
GSK Investigational Site
Copenhagen, 2100, Denmark
-
GSK Investigational Site
Bordeaux, 33076, France
-
GSK Investigational Site
Lyon, 69373, France
-
GSK Investigational Site
Paris, 75248, France
-
GSK Investigational Site
Strasbourg, 67098, France
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Bologna, 40138, Italy
-
GSK Investigational Site
Naples, 80123, Italy
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Madrid, 28009, Spain
-
GSK Investigational Site
Madrid, 28046, Spain
-
GSK Investigational Site
Valencia, 46026, Spain
Conditions
Explore the condition pages connected to this study.